Loading company…
Typewriter Therapeutics develops RNA medicines and gene insertion platforms for cancer, autoimmune, and rare genetic diseases.
Founded in 2025 and based in Massachusetts, Typewriter Therapeutics develops RNA-based genetic medicines and gene insertion platforms. Its work targets cancer, autoimmune diseases, and rare genetic diseases. The company is at the Series A stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in